☆ 4.6 Letter

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 182, Issue 4, Pages 583-586

Publisher

WILEY
DOI: 10.1111/bjh.14820

Keywords

inotuzumab ozogamicin; B-cell non-Hodgkin lymphoma; CD22+; antibody-drug conjugate; rituximab

Categories

Hematology

Funding

  1. Pfizer Inc.
  2. NATIONAL CANCER INSTITUTE [R01CA152923, P30CA016672] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.